With representatives from over 30 countries and 20 international organisations, the Eco Expo Central Asia 2025 served as a ...

The baseline characteristics are summarized below: With regards to safety and tolerability – in the phase 1a, evaluating increasing doses of SHR-1501 alone (200, 400, and 600 µg), and phase 1b part of ...

The 6th Annual Hi Fit Expo is back, bringing Hawai‘i’s biggest fitness festival to life once again — and this year, it’s bigger, bolder, and more community-driven than ever. Headlined by ...

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 ...

Saudi Arabia took a major step toward hosting Expo 2030 Riyadh after the General Assembly of the Bureau International des Expositions (BIE) on Tuesday unanimously approved the Kingdom’s registration ...

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, the “Company”), a clinical-stage biotech company developing oral therapies for autoimmune, inflammatory ...

City commissioners approved a $30,600 agreement with Smith & Oakes, Inc. on June 3 to design the first phase of the water line replacement.

Chinese solar giant partners with TÜV NORD and CTC to launch a white paper detailing advance in TOPCon technology and commercial performance of its latest Tiger Neo 3.0 modules.

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to begin a phase 2/3 pivotal confirmatory trial of OCU410ST. OCU410ST uses an ...

To our knowledge, IMforte is the first phase 3 trial to meet the primary endpoints of progression-free survival and overall survival in the first-line maintenance setting in ES-SCLC. In IMforte, ...

Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib ...